Search

Your search keyword '"Goetzinger F."' showing total 14 results
Start Over Author "Goetzinger F."

Refine your results

more »

more »

more »
14 results on '"Goetzinger F."'

4. Status of the EDELWEISS Experiment

Author

De Jésus, M., Benoit, A., Bergé, L., Broniatowski, A., Caussignac, M., Chambon, B., Chapellier, M., Chardin, G., Charvin, Ph., Drain, D., Dumoulin, L., Garoche, P., Gascon, J., Goetzinger, F., Goldbach, C., Goyot, M., Gros, M., Hadjout, J-P., Hervé, S., Juillard, A., de Lesquen, A., Loidl, M., Mallet, J., Mangin, J., Marnieros, S., Martin, M., Martineau, O., Mirabolfathi, N., Miramonti, L., Mosca, L., Navick, X-F., Nollez, G., Pari, P., Patru, F., Pastor, Ch., Simon, E., Stern, M., Torre, J-P., Vagneron, L., and Cline, David B., editor

Published
2001
Full Text
View/download PDF

5. Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑ Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study

Author

Noguera-Julian A., Calzada-Hernandez J., Brinkmann F., Roy R. B., Bilogortseva O., Buettcher M., Carvalho I., Chechenyeva V., Falcon L., Goetzinger F., Guerrero-Laleona C., Hoffmann P., Jelusic M., Niehues T., Ozere I., Shackley F., Suciliene E., Welch S. B., Scholvinck E. H., Ritz N., Tebruegge M., Curtis N., Villanueva P., Marais B., Britton P., Clark J., Pichler J., Zschocke A., Bogyi M., Dreesman A., Mouchet F., Velizarova S., Pavic I., Nygaard U., Pulsen A., Kontturi A., Salo E., Chadelat K., Kruger R., Tee S., Ahrens F., Barker M., Zimmermann T., Schulze-Sturm U., Kaiser-Labusch P., Tsolia M., Ghanaie O. M., Buonsenso D., Lo Vecchio A., Ivaskeviciene I., Vilc V., Smyrnaios A., Arbore A. S., Starshinova A., Solovic I., Krivec U., Aldeco M., Espiau M., Soriano-Arandes A., Neth O., Santiago B., Gomez-Pastrana D., Blazquez D., Bustillo M., Perez-Porcuna T. M., Cilleruelo M. J., Kotz K., Bennet R., Relly C., Niederer-Loher A., Rochat I., Pavskyi S., Riordan A., Doherty C., Bamford A., Shingadia D., Emonts M., Ferreras-Antolin L., McMaster P., Moriarty P., Noguera-Julian, A., Calzada-Hernandez, J., Brinkmann, F., Roy, R. B., Bilogortseva, O., Buettcher, M., Carvalho, I., Chechenyeva, V., Falcon, L., Goetzinger, F., Guerrero-Laleona, C., Hoffmann, P., Jelusic, M., Niehues, T., Ozere, I., Shackley, F., Suciliene, E., Welch, S. B., Scholvinck, E. H., Ritz, N., Tebruegge, M., Curtis, N., Villanueva, P., Marais, B., Britton, P., Clark, J., Pichler, J., Zschocke, A., Bogyi, M., Dreesman, A., Mouchet, F., Velizarova, S., Pavic, I., Nygaard, U., Pulsen, A., Kontturi, A., Salo, E., Chadelat, K., Kruger, R., Tee, S., Ahrens, F., Barker, M., Zimmermann, T., Schulze-Sturm, U., Kaiser-Labusch, P., Tsolia, M., Ghanaie, O. M., Buonsenso, D., Lo Vecchio, A., Ivaskeviciene, I., Vilc, V., Smyrnaios, A., Arbore, A. S., Starshinova, A., Solovic, I., Krivec, U., Aldeco, M., Espiau, M., Soriano-Arandes, A., Neth, O., Santiago, B., Gomez-Pastrana, D., Blazquez, D., Bustillo, M., Perez-Porcuna, T. M., Cilleruelo, M. J., Kotz, K., Bennet, R., Relly, C., Niederer-Loher, A., Rochat, I., Pavskyi, S., Riordan, A., Doherty, C., Bamford, A., Shingadia, D., Emonts, M., Ferreras-Antolin, L., Mcmaster, P., and Moriarty, P.

Subjects
reactivation, Disease, anti-TNF-alpha, 0302 clinical medicine, Medicine, children, 030212 general & internal medicine, JUVENILE IDIOPATHIC ARTHRITIS, Child, Anti–TNF-alpha, RISK, Latent tuberculosis, GAMMA RELEASE ASSAYS, Miliary tuberculosi, SERIOUS INFECTION, Infectious Diseases, tuberculosis, anti–TNF-alpha, medicine.drug, miliary tuberculosis, Microbiology (medical), Adult, medicine.medical_specialty, Miliary tuberculosis, Tuberculosis, Adolescent, CORTICOSTEROIDS, Tuberculin, DIAGNOSIS, CLASSIFICATION, 03 medical and health sciences, Necrosis, Latent Tuberculosis, Internal medicine, SURVEILLANCE, INFLIXIMAB, Humans, Retrospective Studies, 030203 arthritis & rheumatology, business.industry, Tuberculin Test, Tumor Necrosis Factor-alpha, Retrospective cohort study, medicine.disease, FACTOR INHIBITORS, Infliximab, Clinical research, business, Interferon-gamma Release Tests
Abstract

Background In adults, anti–tumor necrosis factor-α (TNF-α) therapy is associated with progression of latent tuberculosis (TB) infection (LTBI) to TB disease, but pediatric data are limited. Methods Retrospective multicenter study within the Paediatric Tuberculosis Network European Trials Group, capturing patients Results Sixty-six tertiary healthcare institutions providing care for children with TB participated. Nineteen cases were identified: Crohn’s disease (n = 8; 42%) and juvenile idiopathic arthritis (n = 6; 32%) were the commonest underlying conditions. Immune-based TB screening (tuberculin skin test and/or interferon-γ release assay) was performed in 15 patients before commencing anti–TNF-α therapy but only identified 1 LTBI case; 13 patients were already receiving immunosuppressants at the time of screening. The median interval between starting anti–TNF-α therapy and TB diagnosis was 13.1 (IQR, 7.1–20.3) months. All cases presented with severe disease, predominantly miliary TB (n = 14; 78%). One case was diagnosed postmortem. TB was microbiologically confirmed in 15 cases (79%). The median duration of anti-TB treatment was 50 (IQR, 46–66) weeks. Five of 15 (33%) cases who had completed TB treatment had long-term sequelae. Conclusions LTBI screening is frequently false-negative in this patient population, likely due to immunosuppressants impairing test performance. Therefore, patients with immune-mediated diseases should be screened for LTBI at the point of diagnosis, before commencing immunosuppressive medication. Children on anti–TNF-α therapy are prone to severe TB disease and significant long-term morbidity. Those observations underscore the need for robust LTBI screening programs in this high-risk patient population, even in low-TB-prevalence settings.

Published
2019

6. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study

Author

Goetzinger, F, Santiago-Garcia, B, Noguera-Julian, A, Lanaspa, M, Lancella, L, Carducci, FIC, Gabrovska, N, Velizarova, S, Prunk, P, Osterman, V, Krivec, U, Lo Vecchio, A, Shingadia, D, Soriano-Arandes, A, Melendo, S, Lanari, M, Pierantoni, L, Wagner, N, L'Huillier, AG, Heininger, U, Ritz, N, Bandi, S, Krajcar, N, Roglic, S, Santos, M, Christiaens, C, Creuven, M, Buonsenso, D, Welch, SB, Bogyi, M, Brinkmann, F, Tebruegge, M, Goetzinger, F, Santiago-Garcia, B, Noguera-Julian, A, Lanaspa, M, Lancella, L, Carducci, FIC, Gabrovska, N, Velizarova, S, Prunk, P, Osterman, V, Krivec, U, Lo Vecchio, A, Shingadia, D, Soriano-Arandes, A, Melendo, S, Lanari, M, Pierantoni, L, Wagner, N, L'Huillier, AG, Heininger, U, Ritz, N, Bandi, S, Krajcar, N, Roglic, S, Santos, M, Christiaens, C, Creuven, M, Buonsenso, D, Welch, SB, Bogyi, M, Brinkmann, F, and Tebruegge, M

Abstract

BACKGROUND: To date, few data on paediatric COVID-19 have been published, and most reports originate from China. This study aimed to capture key data on children and adolescents with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection across Europe to inform physicians and health-care service planning during the ongoing pandemic. METHODS: This multicentre cohort study involved 82 participating health-care institutions across 25 European countries, using a well established research network-the Paediatric Tuberculosis Network European Trials Group (ptbnet)-that mainly comprises paediatric infectious diseases specialists and paediatric pulmonologists. We included all individuals aged 18 years or younger with confirmed SARS-CoV-2 infection, detected at any anatomical site by RT-PCR, between April 1 and April 24, 2020, during the initial peak of the European COVID-19 pandemic. We explored factors associated with need for intensive care unit (ICU) admission and initiation of drug treatment for COVID-19 using univariable analysis, and applied multivariable logistic regression with backwards stepwise analysis to further explore those factors significantly associated with ICU admission. FINDINGS: 582 individuals with PCR-confirmed SARS-CoV-2 infection were included, with a median age of 5·0 years (IQR 0·5-12·0) and a sex ratio of 1·15 males per female. 145 (25%) had pre-existing medical conditions. 363 (62%) individuals were admitted to hospital. 48 (8%) individuals required ICU admission, 25 (4%) mechanical ventilation (median duration 7 days, IQR 2-11, range 1-34), 19 (3%) inotropic support, and one (<1%) extracorporeal membrane oxygenation. Significant risk factors for requiring ICU admission in multivariable analyses were being younger than 1 month (odds ratio 5·06, 95% CI 1·72-14·87; p=0·0035), male sex (2·12, 1·06-4·21; p=0·033), pre-existing medical conditions (3·27, 1·67-6·42; p=0·0015), and presence of lower respiratory tract infection signs or sy

Published
2020

10. Status of the EDELWEISS experiment

Author

Chardin, G., De Jésus, M., Benoit, Angélique, Broniatowski, A., Berge, L., Caussignac, M., Chambon, B., Chapellier, M., Charvin, P., Drain, D., Dumoulin, L., Garoche, P., Gascon, J., Goetzinger, F., Goldbach, C., Goyot, M., Gros, M., Hadjout, J.-P., Herve, S., Juillard, A., De Lesquen, A., Loidl, M., Mallet, J., Mangin, J., Marnieros, S., Martin, M., Martineau, O., Mirabolfathi, N., Miramonti, L., Mosca, L., Navick, X.F., Nollez, G., Pari, P., Pastor, C., Simon, E., Stern, M., Torre, J-P., Vagneron, L., Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), Centre de Spectrométrie Nucléaire et de Spectrométrie de Masse (CSNSM), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), and EDELWEISS

Subjects
[PHYS.ASTR.CO]Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], [SDU.ASTR]Sciences of the Universe [physics]/Astrophysics [astro-ph]
Abstract

Manoir

Published
1999

13. Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑ Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study.

Author

Noguera-Julian A, Calzada-Hernández J, Brinkmann F, Basu Roy R, Bilogortseva O, Buettcher M, Carvalho I, Chechenyeva V, Falcón L, Goetzinger F, Guerrero-Laleona C, Hoffmann P, Jelusic M, Niehues T, Ozere I, Shackley F, Suciliene E, Welch SB, Schölvinck EH, Ritz N, and Tebruegge M

Subjects
Adolescent, Adult, Child, Humans, Interferon-gamma Release Tests, Necrosis, Retrospective Studies, Tuberculin Test, Tumor Necrosis Factor-alpha, Latent Tuberculosis diagnosis, Latent Tuberculosis epidemiology, Tuberculosis epidemiology
Abstract

Background: In adults, anti-tumor necrosis factor-α (TNF-α) therapy is associated with progression of latent tuberculosis (TB) infection (LTBI) to TB disease, but pediatric data are limited., Methods: Retrospective multicenter study within the Paediatric Tuberculosis Network European Trials Group, capturing patients <18 years who developed TB disease during anti-TNF-α therapy., Results: Sixty-six tertiary healthcare institutions providing care for children with TB participated. Nineteen cases were identified: Crohn's disease (n = 8; 42%) and juvenile idiopathic arthritis (n = 6; 32%) were the commonest underlying conditions. Immune-based TB screening (tuberculin skin test and/or interferon-γ release assay) was performed in 15 patients before commencing anti-TNF-α therapy but only identified 1 LTBI case; 13 patients were already receiving immunosuppressants at the time of screening. The median interval between starting anti-TNF-α therapy and TB diagnosis was 13.1 (IQR, 7.1-20.3) months. All cases presented with severe disease, predominantly miliary TB (n = 14; 78%). One case was diagnosed postmortem. TB was microbiologically confirmed in 15 cases (79%). The median duration of anti-TB treatment was 50 (IQR, 46-66) weeks. Five of 15 (33%) cases who had completed TB treatment had long-term sequelae., Conclusions: LTBI screening is frequently false-negative in this patient population, likely due to immunosuppressants impairing test performance. Therefore, patients with immune-mediated diseases should be screened for LTBI at the point of diagnosis, before commencing immunosuppressive medication. Children on anti-TNF-α therapy are prone to severe TB disease and significant long-term morbidity. Those observations underscore the need for robust LTBI screening programs in this high-risk patient population, even in low-TB-prevalence settings., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results